Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Am Heart J
; 235: 12-23, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33577800
Full text:
1
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Terapias_biologicas
/
Aromoterapia
Main subject:
Outpatients
/
Thrombosis
/
Factor Xa Inhibitors
/
Rivaroxaban
/
COVID-19
/
Hospitalization
Type of study:
Clinical_trials
/
Etiology_studies
Language:
En
Journal:
Am Heart J
Year:
2021
Type:
Article